Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects

NCT07219940 is registered in ClinicalTrials.gov with Shine-On Biomedical Co., Ltd. as lead sponsor.

NCT NCT07219940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07219940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label and Dose-escalation Phase I Clinical Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of HLA-G-targeted Exosome (SOB100) in Healthy Subjects
Lead sponsor
Shine-On Biomedical Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2025
Completion date
March 31, 2027
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

exosome, healthy subjects, targeted therapy